Drugs / HZ/su
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05219253 | Feb → Oct 2022 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-19 | GlaxoSmithKline | Results New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-19 | GlaxoSmithKline | New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over gsk.com ↗ |
| 2017-09-13 | GlaxoSmithKline | FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZ/su | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219253 ↗ |
| Modality | Vaccine | “HZ/su vaccine” NCT05219253 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05219253 ↗ |